Predict your next investment

HUYA Bioscience International company logo
HEALTHCARE | Biotechnology
huyabio.com

See what CB Insights has to offer

Founded Year

2004

Stage

Loan | Alive

Total Raised

$61.29M

Last Raised

$680K | 1 yr ago

About HUYA Bioscience International

HUYA Bioscience International enables and accelerates the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas and the largest team of scientists working with Chinese innovators, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan and in eight strategic locations across China, with joint headquarters in San Diego and Shanghai. HUYA identifies and advances promising drug candidates globally.

HUYA Bioscience International Headquarter Location

12531 High Bluff Drive Suite 138

San Diego, California, 92130,

United States

858-798-8800

Latest HUYA Bioscience International News

HUYA Bioscience International Presents Positive Data On HBI-8000 at Society for Immunotherapy of Cancer Meeting

Nov 9, 2020

HUYA Bioscience International Presents Positive Data On HBI-8000 at Society for Immunotherapy of Cancer Meeting HUYA Bioscience International Presents Positive Data On HBI-8000 at Society for Immunotherapy of Cancer Meeting Share Last updated Nov 9, 2020 SAN DIEGO, Nov. 9, 2020 /PRNewswire/ — HUYA Bioscience International (HUYABIOTM), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the presentation of results from an ongoing Phase II study evaluating the efficacy and safety of HBI-8000 in combination with nivolumab in patients with advanced metastatic melanoma. The results were presented at the Society for Immunotherapy of Cancer’s virtual 35th Anniversary Annual Meeting (SITC 2020; Abstract # 797). “Data from this combination study are very encouraging,” said lead investigator, Nikhil I. Khushalani, MD, Vice Chair and Senior Member of the Department of Cutaneous Oncology at Moffitt Cancer Center in Tampa, Florida. “As standard of care, patients with metastatic melanoma are routinely treated with a PD-1 inhibitor such as nivolumab or pembrolizumab. “When nivolumab was combined with HBI-8000, it appears the efficacy was enhanced while safety profile remains quite acceptable. The patients on the study are being followed for long- term outcomes. A Phase III study to further investigate the efficacy and safety of this combination of therapy is now planned.” Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO, said, “These data further demonstrate the promise of HBI-8000 in cancer therapy. This builds on the momentum from our October 2020 regulatory submission to the Japanese Pharmaceuticals and Medical Devices Agency for HBI-8000 monotherapy for relapsed or refractory (R/R) adult …

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing HUYA Bioscience International

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

HUYA Bioscience International is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

HUYA Bioscience International Patents

HUYA Bioscience International has filed 13 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Monoclonal antibodies
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/23/2020

6/1/2021

Cardiac arrhythmia, Antiarrhythmic agents, Cardiac electrophysiology, Calcium channel blockers, Potassium channel blockers

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/23/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/1/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cardiac arrhythmia, Antiarrhythmic agents, Cardiac electrophysiology, Calcium channel blockers, Potassium channel blockers

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

HUYA Bioscience International Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

HUYA Bioscience International Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.